EGFR and non-small cell lung carcinoma: While LIPI was not possible in our study due to limited patient numbers, these findings suggest that LIPI may be a useful biomarker for chemotherapy and EGFR-TKI therapy in specific subsets of NSCLC and highlights the need to evaluate such biomarkers based on histological and genetic subtypes.